Summary & Overview
CPT 54200: Penile Injection for Peyronie Disease
CPT code 54200 designates a penile injection procedure used to treat Peyronie disease by delivering medication into the external penis to reduce plaque-related curvature. This code matters nationally because Peyronie disease can cause pain, functional impairment, and quality-of-life effects; injectable therapies represent a common, minimally invasive management option and drive outpatient urology procedure volumes. Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what CPT code 54200 represents clinically, where the service is typically provided, and how it fits into urologic outpatient care. The publication summarizes common billing contexts and expected places of service for this procedure, highlights typical modifiers and coding considerations (Data not available in the input for payer-specific rates and diagnosis mappings), and provides clinical context about why injectable therapy is used for Peyronie disease. This national overview is intended to orient clinicians, billing staff, and policy analysts to the code’s clinical role and billing classification without state-specific details.
Billing Code Overview
CPT code 54200 describes an injection of medication into the external structures of the penis performed for treatment of Peyronie disease, a condition characterized by abnormal curvature of the erect penis. This procedure is a penile injection therapy intended to address plaque-related curvature and improve penile form and function.
-
Service type: Office-based or clinic procedural injection
-
Typical site of service: Urology clinic or outpatient ambulatory care setting
Clinical & Coding Specifications
Clinical Context
A 52-year-old man with a 1-year history of progressive penile curvature and painful erections presents to a urology clinic. He reports difficulty with sexual intercourse and localized penile plaque on exam consistent with Peyronie disease. Prior conservative management including oral therapies and observation provided inadequate symptom relief. After shared decision-making, the urologist schedules an in-office procedure to deliver intralesional medication into the tunica albuginea of the penis to reduce curvature and improve sexual function.
The clinical workflow includes pre-procedure informed consent, focused genitourinary history and physical exam, measurement and photography of curvature in the erect state (or induced pharmacologic erection), marking the injection site, local anesthesia, sterile technique, and intralesional injection of a collagenase or other approved agent directed into the plaque. The provider documents indication, laterality (if applicable), number of injections, medication and dose, anesthesia, patient tolerance, and post-procedure instructions. Typical follow-up visits assess curvature improvement, adverse events, and need for repeat injections or adjunctive modeling therapies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a distinct E/M visit is provided on the same day as the injection and is documented separately. |